Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Siran Biotechnology is a China-based biopharmaceutical company specializing in the development of innovative RNA therapeutics, including small interfering RNA (siRNA) and mRNA-based drugs. The company utilizes its proprietary delivery platforms, focusing on GalNAc-conjugation for liver-targeted delivery and advanced lipid nanoparticles (LNP) for extrahepatic and mRNA applications. Siran's pipeline primarily addresses high-prevalence conditions within infectious diseases and metabolic disorders, with lead programs targeting Chronic Hepatitis B and hyperlipidemia. By optimizing sequence design and delivery efficiency, the company aims to provide next-generation genetic medicines. Siran is currently advancing its candidate molecules through pre-clinical development and IND-enabling studies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Siran Biotechnology.